MedImmune Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3,000

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 5

  • Investments
  • 21

MedImmune General Information

Description

Developer of drugs for prevention and treatment of infectious disease, autoimmune diseases and cancer. The company undertakes the research and development, manufacture and marketing of biologics to address some of the major medical needs in the healthcare industry.

Contact Information

Formerly Known As
Molecular Vaccines, Inc.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • One MedImmune Way
  • Gaithersburg, MD 20878
  • United States
+1 (301)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Corporate Office
  • One MedImmune Way
  • Gaithersburg, MD 20878
  • United States
+1 (301)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MedImmune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MedImmune‘s full profile, request access.

Request a free trial

MedImmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs for prevention and treatment of infectious disease, autoimmune diseases and cancer. The company under
Biotechnology
Gaithersburg, MD
3,000 As of 2008

Incheon, South Korea
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MedImmune Competitors (59)

One of MedImmune’s 59 competitors is Samsung Bioepis, a Corporate Backed or Acquired company based in Incheon, South Korea.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Samsung Bioepis Corporate Backed or Acquired Incheon, South Korea
Incyte Formerly VC-backed Wilmington, DE
Merck & Co. Corporation Rahway, NJ
Biocon Biologics Formerly PE-Backed Bengaluru, India
BeOne Medicines Formerly PE-Backed Beijing, China
You’re viewing 5 of 59 competitors. Get the full list »

MedImmune Patents

MedImmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026229570-A1 Treatment with anti-tslp antibody Pending 01-May-2025
WO-2026093970-A1 Combination dosage regimens of amylin receptor agonists and glp-1 receptor agonists Pending 01-Nov-2024
US-20260131017-A1 Cd22 antibody and drug conjugates and uses thereof Pending 11-Oct-2024
WO-2026078620-A1 Cd22 antibody and drug conjugates and uses thereof Pending 11-Oct-2024
WO-2026058194-A1 Polypeptide dosage regimens Pending 12-Sep-2024 A61K38/22
To view MedImmune’s complete patent history, request access »

MedImmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MedImmune Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MedImmune‘s full profile, request access.

Request a free trial

MedImmune Investments & Acquisitions (21)

MedImmune’s most recent deal was a Early Stage VC with Corvidia Therapeutics for . The deal was made on 25-Apr-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Corvidia Therapeutics 25-Apr-2018 Early Stage VC Biotechnology
Corvidia Therapeutics 17-Feb-2016 Early Stage VC Biotechnology
Inovio Pharma (Rights to INO-3112 immunotherapy drug) 10-Oct-2015 Corporate Asset Purchase Buildings and Property
Definiens 25-Nov-2014 Merger/Acquisition Other Healthcare Technology Systems
Allozyne 01-Jan-2014 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 21 investments and acquisitions. Get the full list »

MedImmune Exits (11)

MedImmune’s most recent exit was on 25-Apr-2018 from Corvidia Therapeutics. The exit was categorized as with 10 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Corvidia Therapeutics 25-Apr-2018 Completed
  • 10 buyers
Corvidia Therapeutics 17-Feb-2016 Completed
  • 6 buyers
Faeth Therapeutics 01-May-2002 Completed
Applied Molecular Evolution 15-Jun-2000 Completed
  • 7 buyers
Applied Molecular Evolution 11-Sep-1997 Later Stage VC Completed
  • 6 buyers
You’re viewing 5 of 11 exits. Get the full list »

MedImmune Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
MedImmune Ventures Gaithersburg, MD 2002

MedImmune FAQs

  • When was MedImmune founded?

    MedImmune was founded in 1988.

  • Where is MedImmune headquartered?

    MedImmune is headquartered in Gaithersburg, MD.

  • What is the size of MedImmune?

    MedImmune has 3,000 total employees.

  • What industry is MedImmune in?

    MedImmune’s primary industry is Biotechnology.

  • Is MedImmune a private or public company?

    MedImmune is a Private company.

  • What is the current valuation of MedImmune?

    The current valuation of MedImmune is .

  • What is MedImmune’s current revenue?

    The current revenue for MedImmune is .

  • Who are MedImmune’s investors?

    Global Emerging Markets, HealthCare Ventures, Patricia Industries, and Rho Acceleration have invested in MedImmune.

  • Who are MedImmune’s competitors?

    Samsung Bioepis, Incyte, Merck & Co., Biocon Biologics, and BeOne Medicines are some of the 59 competitors of MedImmune.

  • When was MedImmune acquired?

    MedImmune was acquired on 19-Jun-2007.

  • Who acquired MedImmune?

    MedImmune was acquired by AstraZeneca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process